122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I. (December 2022) - Baramidze, A.; Gogishvili, M.; Melkadze, T.; Giorgadze, D.; Penkov, K.D.; Makharadze, T.; Kalinka, E.; Nechaeva, M.; Laktionov, K.; Gessner, C.; Moreno Jaime, B.; Passalacqua, R.; et al.